Allogene Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to ALLO-715, an AlloCAR T™ Cell Therapy in Development for Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 04/21/21
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR™ Candidate, for the Treatment of Patients with Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 04/19/21
Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple MyelomaGlobeNewsWire • 04/12/21
Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 MeetingGlobeNewsWire • 04/10/21
Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/27/21
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/28/21
Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate UpdateGlobeNewsWire • 02/25/21
Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021GlobeNewsWire • 02/18/21
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational MedicineGlobeNewsWire • 01/26/21
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 12/23/20
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell TherapiesGlobeNewsWire • 12/15/20
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of HematologyGlobeNewsWire • 12/07/20
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of HematologyGlobeNewsWire • 12/06/20
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual MeetingGlobeNewsWire • 12/05/20
Allogene Therapeutics (ALLO) Up 8.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/20
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020GlobeNewsWire • 12/02/20
Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference ParticipationGlobeNewsWire • 11/12/20
Allogene Therapeutics' (ALLO) CEO David Chang on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/04/20